Award Data

DESCRIPTION (provided by applicant): The purpose of this project is to develop and test Clear Cues (CC), a signage system for care communities that supports way finding in people with dementia. Way finding is a process through which people use informationin the environment to help them get to their desired destination. It's both the user experience of choosing a path and the design elements t ...

DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (AD). The core symptom of AD is short-term memory impairment. (DSM-IV) In preliminary studies, PD2XXX improved short term memory by over 110% in a well-accepted triple transgenic mouse model of AD (3xTg ...

DESCRIPTION (provided by applicant): Guild proposes to develop an antisense oligomer-based antifungal effective against the human pathogen Aspergillus fumigatus. With a 40%-60% mortality rate, invasive aspergillosis (IA) due to A. fumigatus now surpasses invasive candidiasis as the most frequent fungal cause of death, especially amongst immunocompromised patients. Successful therapy for IA with cu ...

DESCRIPTION (provided by applicant): Human African trypanosomiasis (HAT) is an infectious disease with a large global health burden occurring primarily in Central and Eastern Africa. HAT is 100% fatal if untreated and the current drug therapies suffer frompoor safety profiles, difficult treatment regimens, limited effectiveness, and high costs. Furthermore, drugs that cross the blood brain barrier ...

DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the development of core-binding factor-(CBF)-leukemia and MLL-fusion leukemia. Inactivating RUNX1 mutations are frequently found in patients with acute myeloid leukemia (AML). However, RUNX1 mutation is us ...

Project Summary We propose an instrument system for automated, multiplexed cell- and tissue-based experiments (i.e. tissue microarrays) called the Microfluidic Flow Cell Array (MFCA). The MFCA consists of a microfluidic flow cell array integrated with an inverted fluorescent microscope, allowing the observation of 48 flow chambers simultaneously or an individual chamber at higher magnification. Th ...

Project Summary Evasion of apoptosis is a hallmark of cancer and is associated with oncogenesis, tumor maintenance, and resistance to conventional chemotherapy. BCL-2 was the first identified anti-apoptotic factor and is a member of the BCL-2 family of proteins that cooperate in the regulation of programmed cell death. BCL-2 plays a dominant role in the survival of multiple lymphoid malignancies a ...

DESCRIPTION (provided by applicant): This is the Phase I application of a SBIR project that will be devoted to develop a new fecal DNA test for CRC screening, which will utilize a new tri-marker panel discovered in our preliminary study. CRC is the seconddeadliest cancer in USA. The good news is that early detection along with resection is associated with a five-year survival rate of nearly 100%. ...

Abstract A joint DOE-NCI workshop on ion beam therapy (January 2013, Bethesda, MD) has identified an ambitious set of technological developments needed to support a world-class treatment program for ion beam therapy. One important requirement is the ability to provide detectors that afford single-particle registration at high data rates with high degree of uniformity and minimal interference with ...

DESCRIPTION (provided by applicant): Cancer is a significant health burden in the US and across the globe, representing the second leading cause of death in the US. Cancer cells have metabolic pathways that are altered significantly compared to normal cells. As a result, the pathways involved (lipid biosynthesis for example) are considered excellent targets for therapeutic intervention. The levels ...